Recommended timing of medications that impact sleep and wakefulness: A review of the American Prescribers’ Digital Reference

An appreciable number of medicines have a recommended unique single time-of-day or asymmetrical or unequal-interval multiple-daily administration schedule. Many prescription and over-the-counter (OTC) products, according to administration time, can exert positive or negative impact on nighttime slee...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Sleep medicine reviews 2023-02, Vol.67, p.101714-101714, Article 101714
Hauptverfasser: Khoshnevis, Sepideh, Smolensky, Michael H., Haghayegh, Shahab, Castriotta, Richard J., Hermida, Ramon C., Diller, Kenneth R.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 101714
container_issue
container_start_page 101714
container_title Sleep medicine reviews
container_volume 67
creator Khoshnevis, Sepideh
Smolensky, Michael H.
Haghayegh, Shahab
Castriotta, Richard J.
Hermida, Ramon C.
Diller, Kenneth R.
description An appreciable number of medicines have a recommended unique single time-of-day or asymmetrical or unequal-interval multiple-daily administration schedule. Many prescription and over-the-counter (OTC) products, according to administration time, can exert positive or negative impact on nighttime sleep and daytime wakefulness. Intuitively, medicines used to manage nighttime sleep and daytime wake disorders should be taken, respectively, at night before bedtime and morning after arising. However, some utilized for other medical conditions, if improperly timed, may compromise nocturnal sleep and diurnal attentiveness. We conducted a comprehensive review of the American Prescribers' Digital Reference, internet version of the Physician's Desk Reference, for the recommended scheduling of medications and OTC remedies that can impact sleep and wakefulness. The search revealed several hundred therapies of various classes -- α2-receptor agonists, antidepressants, barbiturates, central nervous system stimulants, benzodiazepines, dopamine agonists, dopamine norepinephrine reuptake inhibitors, selective norepinephrine reuptake inhibitors, eugeroics, γ-aminobutyric acid modulators, H1 and H3-receptor antagonists, melatonin analogues, OTC melatonin-containing products, non-benzodiazepine benzodiazepine-receptor agonists, dual orexin-receptor antagonists, and serotonin modulators -- that have a recommended unique dosing schedule. The tables and text of this article are intended to guide the proper scheduling of these medicines to optimize desired and/or minimize undesired effects.
doi_str_mv 10.1016/j.smrv.2022.101714
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2754047249</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1087079222001277</els_id><sourcerecordid>2754047249</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-3f378f7869e5411ad82e1926b62ad97c44cad173afc653a53759ca43b9a113b73</originalsourceid><addsrcrecordid>eNp9kMtqHDEQRYVJ8PsHsghaZtNjPVuj4M0wiR9giDHxWqilaluTVvdY0th4E_wb_r18ibsZJ8usqijOvVAHoU-UzCih9clqlmN6nDHC2HRQVOygfSo5q5iW8sO4k7mqiNJsDx3kvCKEaEHrXbTHa0k0YXof_b4BN8QIvQePS4ihv8NDiyP44GwJQ59xubcFh7i2ruDcAayx7T1-sr-g3XQ95PwVL3CCxwBPU7TcA15ESGO-x9cJskuhgZT_vLzib-EuFNvhG2ghQe_gCH1sbZfh-H0eotuz7z-XF9XVj_PL5eKqclzWpeItV_NWzWsNUlBq_ZwB1axuama9Vk4IZz1V3LaultxKrqR2VvBGW0p5o_gh-rLtXafhYQO5mBiyg66zPQybbJiSggjFhB5RtkVdGnJO0Jp1CtGmZ0OJmbyblZm8m8m72XofQ5_f-zfN6O5f5K_oETjdAjB-OapKJrswGfAhgSvGD-F__W-iKJYT</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2754047249</pqid></control><display><type>article</type><title>Recommended timing of medications that impact sleep and wakefulness: A review of the American Prescribers’ Digital Reference</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Khoshnevis, Sepideh ; Smolensky, Michael H. ; Haghayegh, Shahab ; Castriotta, Richard J. ; Hermida, Ramon C. ; Diller, Kenneth R.</creator><creatorcontrib>Khoshnevis, Sepideh ; Smolensky, Michael H. ; Haghayegh, Shahab ; Castriotta, Richard J. ; Hermida, Ramon C. ; Diller, Kenneth R.</creatorcontrib><description>An appreciable number of medicines have a recommended unique single time-of-day or asymmetrical or unequal-interval multiple-daily administration schedule. Many prescription and over-the-counter (OTC) products, according to administration time, can exert positive or negative impact on nighttime sleep and daytime wakefulness. Intuitively, medicines used to manage nighttime sleep and daytime wake disorders should be taken, respectively, at night before bedtime and morning after arising. However, some utilized for other medical conditions, if improperly timed, may compromise nocturnal sleep and diurnal attentiveness. We conducted a comprehensive review of the American Prescribers' Digital Reference, internet version of the Physician's Desk Reference, for the recommended scheduling of medications and OTC remedies that can impact sleep and wakefulness. The search revealed several hundred therapies of various classes -- α2-receptor agonists, antidepressants, barbiturates, central nervous system stimulants, benzodiazepines, dopamine agonists, dopamine norepinephrine reuptake inhibitors, selective norepinephrine reuptake inhibitors, eugeroics, γ-aminobutyric acid modulators, H1 and H3-receptor antagonists, melatonin analogues, OTC melatonin-containing products, non-benzodiazepine benzodiazepine-receptor agonists, dual orexin-receptor antagonists, and serotonin modulators -- that have a recommended unique dosing schedule. The tables and text of this article are intended to guide the proper scheduling of these medicines to optimize desired and/or minimize undesired effects.</description><identifier>ISSN: 1087-0792</identifier><identifier>EISSN: 1532-2955</identifier><identifier>DOI: 10.1016/j.smrv.2022.101714</identifier><identifier>PMID: 36509029</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Administration time ; American Prescribers' Digital Reference ; Antidepressive Agents ; Humans ; Medications ; Melatonin - therapeutic use ; Norepinephrine - pharmacology ; Sleep - physiology ; Sleep promotion and disturbance ; Wakefulness - physiology ; Wakefulness promotion and disturbance</subject><ispartof>Sleep medicine reviews, 2023-02, Vol.67, p.101714-101714, Article 101714</ispartof><rights>2022 Elsevier Ltd</rights><rights>Copyright © 2022 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-3f378f7869e5411ad82e1926b62ad97c44cad173afc653a53759ca43b9a113b73</citedby><cites>FETCH-LOGICAL-c356t-3f378f7869e5411ad82e1926b62ad97c44cad173afc653a53759ca43b9a113b73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1087079222001277$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36509029$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Khoshnevis, Sepideh</creatorcontrib><creatorcontrib>Smolensky, Michael H.</creatorcontrib><creatorcontrib>Haghayegh, Shahab</creatorcontrib><creatorcontrib>Castriotta, Richard J.</creatorcontrib><creatorcontrib>Hermida, Ramon C.</creatorcontrib><creatorcontrib>Diller, Kenneth R.</creatorcontrib><title>Recommended timing of medications that impact sleep and wakefulness: A review of the American Prescribers’ Digital Reference</title><title>Sleep medicine reviews</title><addtitle>Sleep Med Rev</addtitle><description>An appreciable number of medicines have a recommended unique single time-of-day or asymmetrical or unequal-interval multiple-daily administration schedule. Many prescription and over-the-counter (OTC) products, according to administration time, can exert positive or negative impact on nighttime sleep and daytime wakefulness. Intuitively, medicines used to manage nighttime sleep and daytime wake disorders should be taken, respectively, at night before bedtime and morning after arising. However, some utilized for other medical conditions, if improperly timed, may compromise nocturnal sleep and diurnal attentiveness. We conducted a comprehensive review of the American Prescribers' Digital Reference, internet version of the Physician's Desk Reference, for the recommended scheduling of medications and OTC remedies that can impact sleep and wakefulness. The search revealed several hundred therapies of various classes -- α2-receptor agonists, antidepressants, barbiturates, central nervous system stimulants, benzodiazepines, dopamine agonists, dopamine norepinephrine reuptake inhibitors, selective norepinephrine reuptake inhibitors, eugeroics, γ-aminobutyric acid modulators, H1 and H3-receptor antagonists, melatonin analogues, OTC melatonin-containing products, non-benzodiazepine benzodiazepine-receptor agonists, dual orexin-receptor antagonists, and serotonin modulators -- that have a recommended unique dosing schedule. The tables and text of this article are intended to guide the proper scheduling of these medicines to optimize desired and/or minimize undesired effects.</description><subject>Administration time</subject><subject>American Prescribers' Digital Reference</subject><subject>Antidepressive Agents</subject><subject>Humans</subject><subject>Medications</subject><subject>Melatonin - therapeutic use</subject><subject>Norepinephrine - pharmacology</subject><subject>Sleep - physiology</subject><subject>Sleep promotion and disturbance</subject><subject>Wakefulness - physiology</subject><subject>Wakefulness promotion and disturbance</subject><issn>1087-0792</issn><issn>1532-2955</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtqHDEQRYVJ8PsHsghaZtNjPVuj4M0wiR9giDHxWqilaluTVvdY0th4E_wb_r18ibsZJ8usqijOvVAHoU-UzCih9clqlmN6nDHC2HRQVOygfSo5q5iW8sO4k7mqiNJsDx3kvCKEaEHrXbTHa0k0YXof_b4BN8QIvQePS4ihv8NDiyP44GwJQ59xubcFh7i2ruDcAayx7T1-sr-g3XQ95PwVL3CCxwBPU7TcA15ESGO-x9cJskuhgZT_vLzib-EuFNvhG2ghQe_gCH1sbZfh-H0eotuz7z-XF9XVj_PL5eKqclzWpeItV_NWzWsNUlBq_ZwB1axuama9Vk4IZz1V3LaultxKrqR2VvBGW0p5o_gh-rLtXafhYQO5mBiyg66zPQybbJiSggjFhB5RtkVdGnJO0Jp1CtGmZ0OJmbyblZm8m8m72XofQ5_f-zfN6O5f5K_oETjdAjB-OapKJrswGfAhgSvGD-F__W-iKJYT</recordid><startdate>202302</startdate><enddate>202302</enddate><creator>Khoshnevis, Sepideh</creator><creator>Smolensky, Michael H.</creator><creator>Haghayegh, Shahab</creator><creator>Castriotta, Richard J.</creator><creator>Hermida, Ramon C.</creator><creator>Diller, Kenneth R.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202302</creationdate><title>Recommended timing of medications that impact sleep and wakefulness: A review of the American Prescribers’ Digital Reference</title><author>Khoshnevis, Sepideh ; Smolensky, Michael H. ; Haghayegh, Shahab ; Castriotta, Richard J. ; Hermida, Ramon C. ; Diller, Kenneth R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-3f378f7869e5411ad82e1926b62ad97c44cad173afc653a53759ca43b9a113b73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Administration time</topic><topic>American Prescribers' Digital Reference</topic><topic>Antidepressive Agents</topic><topic>Humans</topic><topic>Medications</topic><topic>Melatonin - therapeutic use</topic><topic>Norepinephrine - pharmacology</topic><topic>Sleep - physiology</topic><topic>Sleep promotion and disturbance</topic><topic>Wakefulness - physiology</topic><topic>Wakefulness promotion and disturbance</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Khoshnevis, Sepideh</creatorcontrib><creatorcontrib>Smolensky, Michael H.</creatorcontrib><creatorcontrib>Haghayegh, Shahab</creatorcontrib><creatorcontrib>Castriotta, Richard J.</creatorcontrib><creatorcontrib>Hermida, Ramon C.</creatorcontrib><creatorcontrib>Diller, Kenneth R.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Sleep medicine reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Khoshnevis, Sepideh</au><au>Smolensky, Michael H.</au><au>Haghayegh, Shahab</au><au>Castriotta, Richard J.</au><au>Hermida, Ramon C.</au><au>Diller, Kenneth R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recommended timing of medications that impact sleep and wakefulness: A review of the American Prescribers’ Digital Reference</atitle><jtitle>Sleep medicine reviews</jtitle><addtitle>Sleep Med Rev</addtitle><date>2023-02</date><risdate>2023</risdate><volume>67</volume><spage>101714</spage><epage>101714</epage><pages>101714-101714</pages><artnum>101714</artnum><issn>1087-0792</issn><eissn>1532-2955</eissn><abstract>An appreciable number of medicines have a recommended unique single time-of-day or asymmetrical or unequal-interval multiple-daily administration schedule. Many prescription and over-the-counter (OTC) products, according to administration time, can exert positive or negative impact on nighttime sleep and daytime wakefulness. Intuitively, medicines used to manage nighttime sleep and daytime wake disorders should be taken, respectively, at night before bedtime and morning after arising. However, some utilized for other medical conditions, if improperly timed, may compromise nocturnal sleep and diurnal attentiveness. We conducted a comprehensive review of the American Prescribers' Digital Reference, internet version of the Physician's Desk Reference, for the recommended scheduling of medications and OTC remedies that can impact sleep and wakefulness. The search revealed several hundred therapies of various classes -- α2-receptor agonists, antidepressants, barbiturates, central nervous system stimulants, benzodiazepines, dopamine agonists, dopamine norepinephrine reuptake inhibitors, selective norepinephrine reuptake inhibitors, eugeroics, γ-aminobutyric acid modulators, H1 and H3-receptor antagonists, melatonin analogues, OTC melatonin-containing products, non-benzodiazepine benzodiazepine-receptor agonists, dual orexin-receptor antagonists, and serotonin modulators -- that have a recommended unique dosing schedule. The tables and text of this article are intended to guide the proper scheduling of these medicines to optimize desired and/or minimize undesired effects.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>36509029</pmid><doi>10.1016/j.smrv.2022.101714</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1087-0792
ispartof Sleep medicine reviews, 2023-02, Vol.67, p.101714-101714, Article 101714
issn 1087-0792
1532-2955
language eng
recordid cdi_proquest_miscellaneous_2754047249
source MEDLINE; Elsevier ScienceDirect Journals
subjects Administration time
American Prescribers' Digital Reference
Antidepressive Agents
Humans
Medications
Melatonin - therapeutic use
Norepinephrine - pharmacology
Sleep - physiology
Sleep promotion and disturbance
Wakefulness - physiology
Wakefulness promotion and disturbance
title Recommended timing of medications that impact sleep and wakefulness: A review of the American Prescribers’ Digital Reference
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T01%3A55%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recommended%20timing%20of%20medications%20that%20impact%20sleep%20and%20wakefulness:%20A%20review%20of%20the%20American%20Prescribers%E2%80%99%20Digital%20Reference&rft.jtitle=Sleep%20medicine%20reviews&rft.au=Khoshnevis,%20Sepideh&rft.date=2023-02&rft.volume=67&rft.spage=101714&rft.epage=101714&rft.pages=101714-101714&rft.artnum=101714&rft.issn=1087-0792&rft.eissn=1532-2955&rft_id=info:doi/10.1016/j.smrv.2022.101714&rft_dat=%3Cproquest_cross%3E2754047249%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2754047249&rft_id=info:pmid/36509029&rft_els_id=S1087079222001277&rfr_iscdi=true